Usefulness of LDL-apheresis for treatment of steroid-resistant nephrotic syndrome

Japanese Journal of Nephrology

Volumn 45, Issue 1, 2003, Pages 25-31

  Yoshizawa, Tsuguto ^a   Suzuki, Toshihide ^a   Kanmatsuse, Katsuo ^a  

^a SURUGADAI NIHON UNIVERSITY HOSPITAL   (Japan)

Author keywords

Focal glomerular sclerosis; LDL apheresis; Minimal change type nephrotic syndrome; Nephrotic syndrome; Thrombin anti thrombin III complex

Indexed keywords

BETA THROMBOGLOBULIN; LOW DENSITY LIPOPROTEIN; PLASMIN; PLASMIN INHIBITOR; STEROID; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; APHERESIS; ARTICLE; BIOCHEMISTRY; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CREATININE CLEARANCE; EQUIPMENT; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HEMODIALYSIS; HUMAN; MALE; NEPHROTIC SYNDROME; PROTEIN URINE LEVEL; REMISSION;

ADULT; AGED; ANTITHROMBIN III; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PEPTIDE HYDROLASES; TREATMENT OUTCOME;

EID: 0037224229     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, Grassi C, Limido D, Pasquali S, Volpini T, Sasdelli M, Locatelli F. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984; 310: 946-50.
2. Yokoyama K, Sakai S, Yamamoto H, Tojo K, Tada N, Suzuki M, Sakai O. Therapeutic LDL apheresis in patients with drug-resistant nephrotic syndrome and with severe glomerular nephritis with hyperlipidemia. Therapeutic Plasmapheresis 1990; 8: 50-5.
3. Marsh JB, Sparks CE. Hepatic secretion of lipoproteins in the rat and the effect of experimental nephrosis. J Clin Invest 1979; 64: 1229-37.
4. Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol 1988; 8: 261-71.
5. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Takemura T, Miki S, Kuwahara T, Takamitsu Y, Tsubakihara Y, the Kansai FGS LDL Apheresis Treatment (K-FLAT) Study Group. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 2001; 89: 408-15.
6. Heslan JM, Branellec AI, Pilatte Y, Lang P, Lagrue G. Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome. Clin Exp Immunol 1991; 86: 157-62.
7. Matsumoto K, Kanmatsuse K. Augmented interleukin-18 production by peripheral blood monocytes in patients with minimal-change nephrotic syndrome. Am J Nephrol 2001; 21: 20-7.
8. Zimmerman SW. Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 1984; 22: 32-8.
9. Fogo A, Hawkins EP, Berry PL, Glick AD, Chiang ML, MacDonell RC Jr, Ichikawa I. Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int 1990; 38: 115-23.
10. Yashiro M, Muso E, Matsushima M, Nagura R, Sawanishi K, Sasayama S. Two-compartment model of cholesterol kinetics for establishment of treatment strategy of LDL apheresis in nephrotic hypercholesterolemia. Blood Purif 1994; 12: 317-26.